In recent years, new technologies and new approaches to scale up HIV testing have emerged. The objective of this paper was to synthesize the body of recent evidence on strategies aimed at increasing the uptake and coverage of HIV testing outside of health care settings in the European Union (EU)/European Economic Area (EEA).
Introduction
In 2010, the European Centre for Disease Prevention and Control (ECDC) produced guidance for HIV testing with an aim to inform the development, monitoring and evaluation of national HIV testing strategies and programmes in the European Union (EU) and European Economic Area (EEA) member states [1] . This guidance recommended expanding HIV testing across a variety of settings across health care services and into the community, in an effort to reduce the high rates of late HIV diagnosis and the proportion of people unaware of their infection.
Despite the finding of a recent evaluation that the guidance has been widely used to develop HIV policies, guidelines, programmes and strategies in the EU/EEA [2] , HIV testing among high-risk populations in Europe has remained low [3] . In 2016, an estimated 25% of people living with HIV were undiagnosed, equivalent to over 300 000 individuals in Europe (EU and non-EU countries) [4] . In addition, high rates of late diagnosis of HIV infection have continued in these countries; over half of people diagnosed in 2016 had a CD4 count of < 350 cells/µL [5] . Studies show that diagnosis of HIV infection promptly after infection is of substantial benefit to the individual, reducing both morbidity and mortality [6, 7] . Furthermore, there is public health benefit, as effective HIV treatment after diagnosis reduces onward transmission [8] .
As a consequence, in 2016, the ECDC launched a project to synthesize the evidence on HIV testing implementation in the EU/EEA, with the aim to document testing interventions, gather case studies of good testing practice and ultimately update the existing testing guidance. This paper focuses on one aspect of the evidence gathering process used to inform the new guidance, summarizing strategies that have been applied with an aim to increase HIV testing outside of health care settings in the EU/EEA and documenting barriers to testing in these settings. In this paper, HIV testing outside of health care settings includes testing occurring in fixed and mobile venues in the community and testing at home.
Testing outside of health care services is a particularly important approach to reach certain groups at higher risk of HIV infection, such as people who inject drugs (PWID), men who have sex with men (MSM), sex workers (SWs) and migrants [9] . These populations are disproportionately burdened by HIV and are often marginalized [5] . Furthermore, these vulnerable groups may not access traditional HIV testing and care services because of stigma and/or laws restricting service use (e.g. for undocumented migrants) [10, 11] . Expanding HIV testing outside of health care settings provides a mechanism of improving testing coverage and identifying undiagnosed infection in at-risk populations [1] . Although previous studies have shown that community testing results in high HIV detection rates [9] , there are challenges to implementation in the EU/EEA, such as service funding and laws restricting non-medical testing [11, 12] .
Methods
The systematic review of the literature, described below, was designed to gather studies that aimed to increase HIV testing or document barriers to testing in the EU/EEA, across all testing settings. It adheres to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13] .
Search strategy
Searches were carried out in OVID Medline, Embase, Psy-cINFO, Scopus and the Cochrane Library of Systematic Reviews on 17 March 2017. Specific search strings were built for HIV, the concept of testing, and EU/EEA geography (Tables S1-S5).
Conference abstracts from the International AIDS Conference, International AIDS Society Conference, European AIDS Clinical Society Conference, Conference on Retroviruses and Opportunistic Infections, HEPHIV and the HIV Drug Therapy Conference were also reviewed for relevance. References of HIV testing guidelines published by the World Health Organization (WHO) and HIV in Europe were also reviewed.
Study inclusion and exclusion
Studies from the database search were included if published between January 2010 and March 2017; this time restriction was applied to capture evidence since the publication of the previous ECDC HIV testing guidelines [1] . Conference proceedings identified through either the database search or the search of the grey literature were included if presented between 2014 and 2017; conference proceedings prior to 2014 were excluded as they were assumed to be published in peer-reviewed journals. Inclusion was restricted to studies of adults (aged ≥ 15 years) conducted in at least one of the 30 EU/EEA countries (Table S6 ) describing approaches to increase HIV testing and/or barriers to testing. Studies were excluded if they focussed on testing following occupational exposure. No language restrictions were applied.
Specific study designs of interest included: observational studies, randomized control trials, economic evaluations and qualitative studies. Systematic reviews were included and reviewed for relevant studies. Case reports, editorials and letters were also included if presenting original data not published elsewhere.
Study selection
A four-stage selection process was used to identify relevant studies, with two independent reviewers at all stages. Disagreement was resolved through consensus and, where required, through independent adjudication by a third party.
Firstly, titles and abstracts were screened based on the inclusion/exclusion criteria. All remaining studies were assessed for eligibility based on the full text. For conference proceedings, authors were contacted for copies of the posters or slides. Where available, these were reviewed at the full-text stage; where not, study inclusion was based on the abstract alone. In the third phase, reference lists from relevant systematic reviews and recently published HIV testing guidance from the WHO and HIV in Europe were reviewed for any other relevant studies.
Finally, further scrutiny of the article was applied during data extraction; articles that made use of the same data set and presented identical outcome measures were de-duplicated, with the most recent or the most complete article included.
Data extraction
Two researchers independently extracted qualitative and quantitative data using a standardized data collection form designed using the Research Electronic Data Capture (RED-Cap) application [14] . All data were extracted in English. The following variables were collected for each included study: study authors, year, study design and type, country, study characteristics (demographics, population subgroups, setting, recruitment and data collection methods) and outcomes (e.g. barriers, coverage, uptake, positivity/reactivity, acceptability and cost-effectiveness). HIV testing intervention studies were categorized based on the strategy(ies) researchers applied in an effort to increase testing, including: testing provision, education programmes, campaigns, communication technologies, clinical decision-making tools and other interventions. Audit studies were considered if they presented evidence on gaps in testing. Nonintervention studies were categorized as economic evaluations, feasibility and/or acceptability studies or studies of barriers to HIV testing. For quantitative outcomes, data were extracted as presented in the study; values were not recalculated based on a predefined approach.
Critical appraisal
Critical appraisal of published studies was carried out at the same time as data extraction and based on National Institute for Health and Clinical Excellence (NICE) checklists [15] and the AXIS quality assessment tool [16] . Each study was assessed for quality and bias by two independent reviewers, except for economic modelling studies which were excluded from critical appraisal.
There were seven critical appraisal questions relevant to every study design and answers to these questions were used to generate a quality rating; studies were rated as being of low (score 0-4), medium (score 5-6) or high quality (score 7). A list of included questions can be found in Table S7 .
A similar approach was used to assign a risk of bias rating to each study based on the four bias fields (selection, reporting, missing and other bias). Articles were rated as having low (score 0-1), medium (score 2-3) or high risk of bias (score 4).
Data analysis
Data were analysed based on the strategy the study applied to try and increase HIV testing, the study setting and the target population, using a descriptive approach. The analyses presented in this paper cover studies on HIV testing initiatives outside of health care settings, such as community and outreach testing. Evidence on HIV testing across health care settings has been published elsewhere [17] .
Results

Study identification and overview
Of the 15 004 de-duplicated records retrieved from the searches, 894 were selected for full-text review following title and abstract screening; 455 underwent data extraction, and, ultimately, 368 studies were included (Figure 1) . Overall, there were 80 studies on HIV testing outside of health care settings, including 41 peer-reviewed articles and 39 conference proceedings.
An overview of these 80 studies can be found in Table 1 . Studies were from 14 of the 30 countries in the EU/EEA, with most set in Northern Europe (n = 37), followed by Southern Europe (n = 27) and Western Europe (n = 12). Four studies were set across multiple EU/EEA countries. There were no studies on HIV testing outside of health care settings from the East, although two of the studies set across Europe covered Eastern EU/EEA countries [55, 95] . The most common country of study was the UK (n = 34), followed by Spain (n = 16) and France (n = 7).
There were a number of interventions carried out in an effort to increase HIV testing outside of health care settings, including: testing provision/implementation (n = 65), testing campaigns (n = 8), communication technologies (n = 2), education and training (n = 4) and other (n = 1) ( Table 1 ). Ten studies applied strategies with multiple components to increase testing. The feasibility/ acceptability of testing outside of health care settings was assessed by 48 studies. The searches captured one economic evaluation and six studies on barriers to testing. There were no audits or studies that used clinical decision-making tools set outside health care settings.
Testing provision outside of health care settings
Of the 65 studies that introduced HIV testing, 56 studies utilized novel HIV testing technologies to improve testing uptake [18, 19, [21] [22] [23] [25] [26] [27] 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [41] [42] [43] 46, 47, [50] [51] [52] 54, [58] [59] [60] [61] [62] [64] [65] [66] [67] [68] [69] [72] [73] [74] [75] [76] [77] [78] 81, 83, 84, [86] [87] [88] [89] [90] 94, 95, 97] , such as rapid testing (n = 38) [19, 21, 26, 27, 29, [33] [34] [35] [36] [37] 39, 41, [50] [51] [52] 54, 58, [60] [61] [62] [64] [65] [66] [67] [68] [69] 73, 76, 78, 81, 83, 84, [86] [87] [88] [89] [90] 95] . Twelve studies provided HIV self-sampling (oral-fluid sample: n = 7 [32, 38, 46, 59, 72, 74, 77] ; blood sample: n = 6 [18, 25, 32, 43, 47, 94] ) and six provided self-testing (oral-fluid: n = 3 [23, 42, 97] ; blood: n = 3 [22, 31, 75] ). Twenty-six studies provided HIV testing as part of an integrated testing programme with: other blood-borne viruses (n = 17) [19, 20, 26, 30, 36, 39, 57, 58, 65, 67, 73, 78, [85] [86] [87] [88] 96] , sexually transmitted infections (STIs) (n = 19) [20, 26, 30, 54, [56] [57] [58] 62, 63, 65, 73, 76, 78, [85] [86] [87] [88] 90, 96] or tuberculosis (n = 1) [67] .
Twenty studies provided non-targeted testing to the general population, while 44 studies provided testing to one or more groups at higher risk of HIV infection. MSM were the group most frequently targeted (n = 31) [20, 21, [25] [26] [27] 30, 32, 38, 39, 46, 51, 54, 58, 60, 61, [63] [64] [65] [66] [72] [73] [74] 76, 77, 81, 86, 87, 89, 94, 96, 97] , followed by: migrants (n = 10) [21, 33, 52, 59, 61, 74, 86, 87, 89, 97] , people who use/inject drugs (PWUD/PWID) (n = 8) [33, 36, 49, 61, 81, 86, 87, 89] , SWs (n = 7) [33, 51, 56, 74, 86, 87, 89] , black and minority ethnic groups (BME) (n = 5) [24, 39, 63, 83, 89] , young people [26, 27, 29, 30, 33, 37, 38, 41, 55, 57, 58, 60, [64] [65] [66] 76, 83, 84, 86, 87, 89, 95, 96] , outreach sites (n = 32) [20] [21] [22] 31, 34, 35, 39, 46, [49] [50] [51] [52] 54, 56, 59, [61] [62] [63] [67] [68] [69] [72] [73] [74] [75] 78, 81, 83, 85, 88, 90, 94] , at home through self-sampling (n = 10) [18, 25, 32, 43, 46, 47, 72, 74, 77, 94] and self-testing (n = 3) [23, 42, 97] and community drug services (n = 2) [19, 36] . Outreach testing activities were run through community mobile units [street-based (n = 9) [21, 22, 31, 34, 35, 49, 68, 69, 75] , event-based (n = 6) [39, 59, 62, 63, 78, 90] and university-based (n = 2) [50, 67] ] and in saunas (n = 6) [20, 46, 51, 54, 72, 94] , gay venues (n = 3) [72, 73, 81] , brothels (n = 2) [51, 56] and homeless services/hostels (n = 2) [85, 88] . One study provided HIV testing to vulnerable migrant populations in a migrant centre [52] and one study provided HIV self-sampling to African migrants in churches and community groups [59] .
As seen in Table 2 , where reported, testing coverage and HIV positivity/reactivity varied within and between population groups targeted and test settings. Very few studies provided data on the proportion of individuals who were offered and/or accepted a test. HIV positivity/reactivity ranged widely by population: MSM: 0.0-11%; BME and migrant groups: 0.0-6.2%; PWID: 1.9-32%; SWs: 0.9-2.1%, and the general population: 0.2-3.2%. Across the studies captured in this review, HIV positivity/reactivity was lowest among homeless people (0.0%) and young people (0.0%). Where studies targeted multiple risk groups, positivity/reactivity ranged from 0.0 to 3.9%. Overall, there were eight studies from this review that reported 0.0% HIV positivity/reactivity [39, 54, 67, 81, 85, 88, 90, 94] ; the numbers of people tested were relatively small [MSM: n = 16-126 [54, 81, 94] ; BME/migrant groups: 26 [39] ; general population: 188 [90] ; homeless people: 58-110 [85, 88] ; young people (students): 512 [67] ].
This review identified a limited number of testing initiatives that demonstrated an increase in HIV testing, as a conseqence of a lack of reporting of baseline data or control data. Only two comparative studies presented data documenting changes to the number tested over time [37, 66] . One study, describing a community-based voluntary counselling and testing service for MSM, showed a scale-up from 951 tests carried out in 2009 to more than 4049 in 2012; reactivity over this period remained stable (3.9% in 2007; 3.4% in 2012) [66] . Another study from Catalonia evaluated the impact of introducing a rapid HIV testing programme in a community testing site network and found that, 1 year after implementation, a 103% increase had been observed in the number of tests performed; again, reactivity remained stable (2.4% in 2006; 2.2% in 2007) [37] .
There were three studies that compared HIV testing in community-based settings to that in health care settings, with varied findings [38, 60, 94] . One study, from France, showed that a higher proportion of MSM accepted a nonmedicalized community-based rapid test compared to a standard medicalized test; this non-medicalized test strategy also reached MSM at higher risk of HIV infection [60] . In contrast, the other two studies found that the proportions of people who accepted a test in the community and in sexual health clinics were similar [38, 94] , with one study finding overall lower uptake in community settings [38] .
Other interventions
Campaigns aimed at the public to improve testing outside of health care settings ranged from small campaigns promoting local testing interventions in magazines, on websites, on social media and/or on the radio (n = 5) [39,60-62,97] to major media campaigns supporting HIV Testing Week (n = 3) [53, 83, 91] . A variety of indicators were used to measure the success of campaigns in increasing testing, such as the additional hours of HIV testing carried out, volume of leaflets/posters distributed, views on social media, editorial coverage, website visits and the number of people accessing the promoted services. However, no studies reported on the change in testing coverage following the campaigns.
Two studies used communication technologies to improve HIV testing rates [72, 73] . One study provided the participants with their results by text message following testing in gay venues [73] and one communicated participant test results online following HIV self-sampling through the Swab2Know project [72] . In both studies, the vast majority of people had received/accessed their test results through these technologies when followed up (99% in both studies).
Three studies incorporated training of medical and non-medical staff on how to perform HIV testing as part of their testing intervention [39, 86, 87] . In one study, health promotion workers were trained in dried-blood spot HIV testing with a one-day education and assessment programme supported by creating a training video available on YouTube [39] . The other two studies provided training to doctors, nurses, psychologists, social workers and peer educators in community testing sites [86, 87] . One study trained people recruited to a mobile outreach unit to perform HIV self-testing under the supervision of a skilled counsellor and 99% received a valid result [22] . None of these interventions documented how education or training increased testing, but following training, 17 801 tests were delivered in community testing sites and outreach settings.
The other intervention implemented with an aim to increase HIV testing was the creation of a national testing network of community organizations working with key risk groups. This network promoted testing at a local level and supported people with reactive test results to link to care [87] . Network members received training in counselling and testing, and were offered information leaflets, rapid testing kits and a standard monitoring questionnaire. In 2016, over 6000 HIV tests were delivered.
Feasibility and acceptability of testing for HIV
The feasibility/acceptability of testing outside of health care settings was assessed by 48 studies (Table 3) [18, [20] [21] [22] [23] [24] [27] [28] [29] [31] [32] [33] [34] 36, 37, 40, [42] [43] [44] [46] [47] [48] 51, 54, 59, 61, 63, 65, 67, 69, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] 85, 87, 90, 93, 97] . Overall, HIV testing was found to be acceptable to people offered testing across community (65-99%) [27, 37, 40, 61] and outreach settings (90-100%) [48, 63, 85] . Both outreach settings and community testing sites seemed to be effective in capturing first-time testers (12-95%) [20] [21] [22] 29, 33, 34, 36, 46, 51, 54, 59, 63, 69, 76, 78, 82, 87, 90] . HIV testing outside of health care settings was also acceptable to the staff offering the tests [67, 85] .
HIV self-sampling was highly acceptable (87-97%) [18, 24, 72, 77, 82] , with people finding the instructions easy to understand [18] and the kits easy to use [18] . The evidence gathered suggests that self-sampling at home is useful in reaching groups at higher risk of HIV infection, such as MSM and black African populations [43, 46, 47] . Selftesting was also considered highly acceptable (71-98%) [23, 28, 31, 42, 97] and easy to do (92-98%) [23, 42, 75, 97] and the results easy to interpret (97-99%), [23, 28, 31, 75] although there was evidence to suggest that acceptability may be dependent on test price and location. [79, 80, 82] Both self-sampling and self-testing reached a high proportion of people who had never previously tested for HIV (10-51%) [18, 24, 42, 43, 47, 72, 79, 97] . Perceived benefits of HIV self-testing included privacy, convenience and immediacy [93] . There were two studies that measured feasibility/acceptability that were not included in Table 3 , as they were not context specific. However, findings suggest a preference for oral-fluid over blood samples for rapid testing [81] and that text-messaging of test results is highly acceptable [73] .
Economic evaluation of HIV testing
There was only one economic evaluation captured in this review. Perelman et al. carried out an economic evaluation of HIV testing for MSM across six community testing services in six European cities (Copenhagen, Paris, Lyon, Athens, Lisbon and Ljubljana) [70] . The cost per HIV test ranged from €41 to €113 and the cost per reactive test from €1966 to €9065, which were among the lowest costs quoted in the literature [70] . Self-sampling acceptable: 66-97% Self-sampling instructions easy to understand (finger-prick): 94% Self-sampling kit easy to use: 80% Preference for self-sampling: 69% Ability of self-sampling to reach risk groups: samples ordered by: MSM, 82 -94%; black Africans, 3.4-42% Home self-sampling cost effective (positivity rate > 0.1%) First time testers: 10-45% [18, 24, 32, 43, 46, 47, 71, 72, 74, 77, 82] HIV self-testing 47-5908 Self-testing acceptable: 71-98% Self-testing easy to do: 92-99% Self-test result easy to interpret: 97-99% Self-testing recommendation to a friend or family member: 89% Ability to interpret self-test results correctly: 99%
Purchasing the self-test if the price was: ≥ €30, 18%; ≥ €20, 40% First time testers: 26-51% [23, 28, 42, 44, 71, 79, 93, 97] MSM, men who have sex with men. *Feasibility/acceptability among people testing unless otherwise specified.
Barriers to HIV testing
There were six studies on barriers to HIV testing outside of health care settings [28, 45, 71, 79, 92, 93] . However, in this systematic review, there were no barriers reported specific to testing in community settings. Five studies described barriers to HIV self-testing [28, 45, 71, 79, 93] from the perspective of the potential tester, including a lack of awareness of self-tests [28, 45] , concern about the capacity to perform self-testing [71, 93] , fear of a reactive result without any support [93] and cost [79] . One study explored barriers to home-sampling among MSM and found men worried about stigma, confidentiality, privacy, the accuracy of the self-sampling test and the lack of opportunity to discuss the results with a health care professional [92] .
Quality assessment
Quality among the 40 peer-reviewed articles that were assessed was variable; 29 (73%) studies were of high quality, eight (20%) were of medium quality and three (7%) were assessed as being of low quality ( Table 1 ). Risk of bias was low in 20 studies (50%), medium in 19 studies (48%) and high in one study (2%) ( Table 1 ).
Discussion
This comprehensive systematic review presents the evidence from the EU/EEA on HIV testing outside of health care settings. Overall, the review highlights that, although HIV testing in community sites and through outreach services is highly feasible, it has been predominantly implemented in a small number of countries. Where reported, uptake and positivity/reactivity rates varied widely, but these outcome measures were generally highest among hard-to-reach groups at higher risk of infection, such as MSM, PWID, SWs and migrants. This review identifies several promising strategies for HIV testing; however, the ability to assess the effectiveness of different initiatives to increase testing was limited by a lack of comparison data. The body of evidence does suggest that testing outside of health care settings is useful in attracting people who have not tested for HIV previously and in re-engaging people previously diagnosed back into care [9] . In addition, this review demonstrates that testing in community and outreach settings is highly acceptable, not only to the people who undergo testing, but also to the people carrying out the tests. Rapid HIV testing outside of health care settings is also highly acceptable and same-day confirmatory testing in community settings is feasible. An economic evaluation of testing MSM in community testing sites suggests that the associated costs are low. Community-based rapid testing may also have the potential to increase HIV test uptake among migrants [98] .
No studies in this review measured the acceptability of lay providers offering HIV testing, although one study found that non-medicalized testing was effective at reaching high-risk MSM who were infrequent testers [60] . Furthermore, existing literature not captured in the review supports utilizing trained lay providers to carry out rapid HIV testing, which was found to be highly effective and acceptable [99] . Encouragingly, there were no studies gathered in the review that documented barriers to HIV testing in the community or by lay providers. It is unclear, however, whether this was because of a lack of research on this topic. In one study, published prior to 2010 and thus not captured in this review, African participants voiced concerns about HIV-related stigma and confidentiality, and doubts about the ability of community-based services to maintain professional standards of care [100] . More research is needed to explore barriers to testing outside of health care settings, as community and outreach testing provides key opportunities to reach highly vulnerable individuals not accessing formal health care services.
Home-sampling and home-testing are strategies that have been implemented in several studies to reach people not accessing traditional HIV testing services. Both strategies have been found to be highly acceptable, easy to use and successful in reaching populations at higher risk for HIV infection. Although, in some studies, people raised concerns about their capacity to perform self-tests, the ability to correctly interpret self-test results was found to be high. For both HIV self-testing and self-sampling, there were concerns about not having sufficient support following a reactive result. The WHO recommends that those with a reactive self-test result should be sign-posted to services for confirmatory testing and peer support [101] . Although the majority of home-sampling and home-testing interventions captured in this review were targeted to MSM, there is evidence that these strategies could be of benefit to other key populations, such as BME groups [43, 47, 101] . Increased HIV testing coverage could be achieved through reduction of the price of selftesting and self-sampling kits and removal of legal and regulatory barriers to use.
Despite evidence for the potential benefits to testing outside of health care settings identified in this review, as of 2016, only one in three countries in Europe had authorized delivery of community-based testing by nonmedical staff and use of home-sampling or self-testing kits was authorized in very few countries [3] . Data from the most recent Dublin Declaration implementation survey indicate that one of the main barriers to effective provision of HIV testing services in the WHO European Region is the availability of community-based services [3] . National guidance should promote the scale-up of testing outside of health care settings to improve testing coverage and reach groups at highest risk of acquiring HIV infection. In addition, legal and regulatory barriers to home-testing and home-sampling should be removed, as well as restrictions on who can offer an HIV test.
It is also essential that testing across non-traditional settings be accompanied by well-defined referral pathways into HIV care for anyone testing positive or with a reactive result. Close coordination between community testing sites and health care facilities is important to ensure successful linkage. Evidence shows that transfer to care was rarely reported in studies of testing outside of health care settings [9] , but, where it was, linkage rates were comparable to linkage from medical settings [102] . Monitoring of linkage to care after HIV diagnosis in community testing sites can often be difficult because of issues with patient confidentiality; only some sites receive information about the result of the confirmatory test and care access and this information is often informal [103, 104] .
This systematic review is comprehensive and used a robust methodology, adherent to PRISMA guidelines, to bring together the evidence on HIV testing outside of health care settings in the EU/EEA. No language restrictions were applied; studies were included in a number of European languages and from a number of countries. Search terms were broad, minimizing the possibility that key studies were missed and minimizing any publication bias. Studies that were critically appraised were of high quality with minimal bias. However, a limitation of this review is that half (49%) of the evidence included had not been peer-reviewed (i.e. conferences or reports), making quality assessment impossible. Synthesizing the evidence was challenging given the difficulty in comparing the findings across studies. HIV testing outcome measures were reported inconsistently, using a variety of definitions; many studies failed to report even the number of people tested and positivity/reactivity. Only one study described the prolonged impact and sustainability of the intervention over time and none presented the impact of testing on HIV incidence/prevalence. Few studies measured baseline testing rates, making it impossible to assess the extent to which the interventions were effective at increasing HIV testing. One limitation to applying the lessons from this review more widely is the limited evidence from Eastern Europe, as strategies to increase testing in one setting may not be valid in other health systems.
Conclusions
This review highlights that testing outside of traditional health care settings plays a key role in diagnosing HIV infection, particularly among people at higher risk of infection and people who have not been tested previously. Testing outside of health care settings is also highly acceptable to both providers and users, making it an essential component of a well-designed, comprehensive HIV testing strategy. Public health professionals, policy advisors and programme managers should consider adapting their national guidelines and programmes to incorporate testing outside health care settings, not only to diversify the test offer, but to reach population groups at higher risk and with potentially poorer access to health care services. Furthermore, effective testing programmes/ strategies should include robust monitoring and evaluation to allow for assessment of programme impact. The evidence from this systematic review was used to inform the ECDC guidance for integrated testing for hepatitis B virus, hepatitis C virus and HIV in Europe [105] . search terms (with VD, DR and LT), ran the searches and compiled the results. SC, SD, LT, AKS, LC, DR, SFJ and VD contributed to systematic review study screening, data extraction and quality assessment along with the wider review working group (as listed in the Acknowledgements). AJAG and LT provided ECDC quality control and directed the ECDC-PHE-CHIP collaboration. 104 
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